Although multiple systemic treatment options are available for men with castration-resistant prostate cancer, there is a paucity of data regarding optimal sequencing of these drugs. A recent study suggests that cabazitaxel exerts antitumour activity in men who have been pretreated with docetaxel and abiraterone or enzalutamide.
- Axel Heidenreich
- Daniel Porres
